Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma That it's dosed monthly probably makes it better suited to psychiatry/addiction settings, where adherence matters a lot I made the table with some inspiration from Lilly's investor deck: investor.lilly.com/static-files/4 interesting stuff
It was cleared by the FDA in April 2023
Our immune system depends on a steady supply of glutathione
Clinical trials show that many people with prediabetes who use semaglutide return to normal blood sugar levels, especially when combined with diet and exercise